Bernstein SocGen cuts Humana stock price target on Stars pressure

Bernstein cut its Humana price target to $211 from $344 while the stock trades at $165.43, near a 52-week low of $163.60 and down ~35% YTD. Humana guided 2026 materially lower than 2025, citing Stars pressure and a planned Medicare Advantage margin (ex‑Stars) increase from ~1% to ~2% but a higher medical loss ratio in 2026, creating meaningful execution risk; Bernstein sees final Stars rates in a 1% to 1.5–2%+ pathway. Additional analyst cuts (Piper Sandler to $182, Barclays to $176, UBS $195), a $1bn 6.625% junior subordinated note sale (net proceeds ~ $986m), and Wolfe Research highlighting activist vulnerability increase near‑term stock sensitivity.

Analysis

Humana’s aggressive plan to materially grow Medicare Advantage membership creates a feedback loop between enrollment mix, rate-setting and medical loss ratio that will play out over multiple benefit cycles. Rapid growth driven by switchers into higher‑rated plans can look accretive initially but materially raises downside tail risk if 2027 pricing doesn’t compensate for a cohort that is chronically higher‑cost; expect MLR volatility to show up in sequential margins and guidance revisions over 2-4 quarters.

The company’s pivot to extend long-duration subordinated funding increases fixed financial obligations and reduces agility to repurchase stock or absorb one-off MLR hits; that in turn raises the bar for activist investors to credibly pressure for operational (network/pricing) fixes rather than pure capital returns. Market catalysts to watch are the October/annual risk‑adjustment/Stars updates and the 2027 rate-setting calendar—any signal that risk adjustment phases are stretched over multiple years would be a multi-quarter positive.

Valuation is pricing a non-trivial probability of prolonged MLR stress, but that is asymmetric: Stars or risk‑adjustment normalization re-rates earnings before the next enrollment cohort fully materializes. Tactical structures that cap downside while retaining upside to a 12–24 month normalization path are preferred to naked equity; credit selection should prefer senior maturities over long subordinated paper because governance/activist outcomes are binary and long subordinated bonds act quasi-equity in that scenario.

Key Decisions for Investors

• Buy HUM 12–18 month call spread (long nearer-dated ITM call, sell higher strike longer-dated call) to capture a 12–24 month Stars/risk‑adjustment normalization. Entry: on any <10% rally from current levels to improve cost basis. Risk/Reward: limited premium loss (~100% of premium) vs multi‑month 30–60% equity upside if normalization reduces projected MLR headwinds.
• Pair trade: Long HUM equity / Short UNH (or another large MA peer) equal dollar notional for 9–12 months to isolate Humana-specific re-rating from sector beta. Entry: scale in on sizeable spread widening; stop-loss: 12–15% on net position. R/R: asymmetric if Humana’s idiosyncratic catalysts (Stars, enrollment mix) turn positive while market remains flat.
• Credit tilt: Buy Humana senior 2–5 year bonds on spread widening around near-term guidance prints, avoid incremental long-dated subordinated paper. Entry: after any headline-driven spread breakouts. R/R: target ~50–100bp spread compression in 6–12 months as short-term uncertainty resolves; principal risk is systemic credit shock increasing funding costs.
• Event hedge: Buy cheap long-dated out-of-the-money puts or protective collars if initiating a material long equity position before the next Stars update. Entry: purchase alongside any sizeable open-enrollment volatility. R/R: protects against a rapid negative selection revelation while preserving upside participation to activist/catalyst-driven rebounds.